Vasconcelos GA, Costa BGG, dos Santos RA, de Faria CD, Schramm Neto FAR, Machado YDJ, Casaes AC, de Oliveira MVL, Fialho TRDS, dos Santos KR, Oliveira BSS, Oliveira RR, de Siqueira IC. Anaphylactic reaction to praziquantel following schistosomiasis treatment.
IJID Reg 2023;
7:268-270. [PMID:
37223089 PMCID:
PMC10200829 DOI:
10.1016/j.ijregi.2023.04.007]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/10/2023] [Accepted: 04/11/2023] [Indexed: 05/25/2023]
Abstract
Praziquantel (PZQ) is a medication used to treat several parasitic infections, including human schistosomiasis. Although this drug commonly causes transient adverse effects, severe hypersensitivity is rare, and only eight cases have been reported worldwide. Herein we report a case of a 13-year-old Brazilian female who developed anaphylaxis, a severe hypersensitive reaction, after taking praziquantel to treat Schistosoma mansoni infection. During a mass drug administration event in a socially vulnerable endemic area of Bahia (Brazil), after taking 60 mg/kg of praziquantel the patient developed rash and generalized edema an hour later, evolving to somnolence and hypotension. Following the anaphylactic episode, she received adequate treatment and recovered approximately 1 day later. Although praziquantel is considered safe, health professionals should be aware of potential life-threatening adverse events.
Collapse